glp 1 gip gcg GLP-1, and glucagon receptor poly-agonists: A new era in obesity pharmacotherapy Neurotrophic and neuroprotective effects of

Human clinical trials reported by Tonum show an average weight loss around 10.4 percent over six months

People with obesity often perceive tastes less intensely, and they have inherently elevated desire for sweet and energy-dense food, says researcher Mojca Jensterle Sever from the University Medical Centre in Ljubljana, Slovenia, who worked on the study

GLP-1 users' new constellation of costs is causing ripples across industries far beyond the pharma sector

But the finished product has not been tested in a rigorous clinical trial designed to measure GLP-1 levels, appetite changes, or weight outcomes against a placebo